Fig. 7

Administration of TAT-CRYAB alleviates DSS-induced intestinal mucosal inflammation in mice. a Administration of TAT-CRYAB intraperitoneally increased CRYAB expression in the colon tissues. Each mouse was injected with 25 μg of TAT-CRYAB intraperitoneally, and killed at indicated times to detect the levels of CRYAB in the colon (one mouse per group). b Schematic diagram of the TAT-CRYAB treatment in DSS-induced colitis (water + PBS group: three mice; water + TAT-CRYAB group: three mice; DSS + PBS group: four mice; DSS + TAT-CRYAB group: four mice). c TAT-CRYAB reduced colitis-induced shortening of colon length, and (d) DAI score; *p < 0.05, **p < 0.01. e TNF-α, IL-6, IL-1β, and IL-8 in DSS-induced colitis were reduced by TAT-CRYAB administration. The cytokines in the colon were assessed by qRT-PCR; *p < 0.05, **p < 0.01, ***p < 0.001. f CRYAB, p-p65, p65, p-IκBα, and IκBα in the colon were analyzed by immunoblotting with specific antibodies. g Representative immunohistochemical images of CRYAB expression in colons from different groups of mice (magnification: ×200, upper panels; ×400, lower panels). h Representative immunohistochemical images of TAT-CRYAB expression examined by the anti-TAT antibody in colons from different groups of mice (magnification: ×200, upper panels; ×400, lower panels). i Representative images of hematoxylin–eosin staining and pathological scores of colon tissues from DSS-exposed mice with or without TAT-CRYAB administration (magnification: ×200, upper panels; ×400, lower panels); *p < 0.05. All data are shown from three independent experiments